The Palo Alto-based firm plans to use the money to further validate its non-invasive, early cancer detection technology.
MD Anderson aims to rapidly collect clinical utility data to support decisions by relevant committees to broadly offer the test and to begin persuading payors to reimburse.
Guardant will help MD Anderson develop new assays and conduct clinical studies, and physicians will be able to order the company's test through an EMR system.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
The results indicate that while blood-based assays can be useful, tissue biopsies should remain the gold standard when available, said one of the study authors.
A small study has found that two next-generation sequencing tests that examined the same cancers uncovered different genetic alterations.
Guardant360 will be the preferred non-invasive assay for clinical testing of patients at the Lurie Cancer Center, and will be used in various research efforts.
The company added three genes to its panel and said it has improved its detection limits, although validation data for these new performance numbers is not yet published.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.